Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking hormone therapy to control the disease. One of the standard treatments for these patients is so-called 'new generation' hormonal therapy. These hormone therapies include apalutamide, enzalutamide, or darolutamide. They work by blocking androgen receptors that play an important role in the growth of prostate cancer. In the case of oligometastatic CRPC, the cancer has

Trial Details

NCT ID
NCT06276465
Phase
PHASE3
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Darolutamide 300 mg
  • Stereotactic body radiation therapy
  • Androgen deprivation therapy
Locations (sample)
  • Lorient, France|47.74817,-3.37177
  • Mougins, France|43.60068,6.99523
  • Saint-Etienne, France|45.43389,4.39
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their wri…
  • Patients aged ≥18 years.
  • Patient with histologically confirmed of adenocarcinoma prostate cancer without small cell or pure endocrine features.
  • Patient with a history of local treatment with curative intent for localised prostate cancer, including surgery or radiotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →